ReviewSeminars in immunopathology2015
Pathological and protective immunity to Pneumocystis infection.
Review in Seminars in immunopathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- Establishment and Preliminary Application of a Multiplex TaqMan Real-Time Fluorescence Quantitative PCR Assay for the Detection ofMicroorganisms · 2026Article
- Integrated dual transcriptome sequencing and experimental validation reveal potential mechanisms of baicalin againstFrontiers in microbiology · 2026Article
- Immune dysregulation inFrontiers in immunology · 2026Article
- Metagenomic next-generation sequencing promotes diagnosis and treatment of Pneumocystis jirovecii pneumonia in non-HIV infected children: a retrospective study.BMC pulmonary medicine · 2024Article
- Embigin Is Highly Expressed on CD4+ and CD8+ T Cells but Is Dispensable for Several T Cell Effector Responses.ImmunoHorizons · 2024Article
- Exploring the Differences in Pneumocystis Pneumonia Infection Between HIV and Non-HIV Patients.Cureus · 2022Review
- Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Article
- Case Report: Successful treatment of severe pneumocystis carinii pneumonia in a case series of primary nephrotic syndrome after receiving anti-CD20 monoclonal antibody therapy.Frontiers in pediatrics · 2022Article
- The diagnostic value of metagenomic next-generation sequencing for identifyingFrontiers in cellular and infection microbiology · 2022Article
- Detection of Cytokines and Collectins in Bronchoalveolar Fluid Samples of Patients Infected withJournal of fungi (Basel, Switzerland) · 2021Article
- A potential mechanism of the onset of immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with advanced adenocarcinoma lung cancer: case report.BMC pulmonary medicine · 2021Article
- Using Routine Laboratory Markers and Immunological Indicators for PredictingFrontiers in immunology · 2021Article
- Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Article
- Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2020Review
- Transcriptomic and Proteomic Approaches to Finding Novel Diagnostic and Immunogenic Candidates inmSphere · 2019Article
- Article
- IL-17 Inversely Correlated with IL-10 via the STAT3 Gene inMediators of inflammation · 2019Article
- Niflumic Acid Reverses Airway Mucus Excess and Improves Survival in the Rat Model of Steroid-InducedFrontiers in microbiology · 2019Article
- Murine models of Pneumocystis infection recapitulate human primary immune disorders.JCI insight · 2018Article
- Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Pneumocystis jirovecii is a common opportunistic infection in the HIV-positive population and is re-emerging as a growing clinical concern in the HIV-negative immunosuppressed population. Newer targeted immunosuppressive therapies and the discovery of rare genetic mutations have furthered our understanding of the immunity required to clear Pneumocystis infection. The immune system can also mount a pathologic response against Pneumocystis following removal of immunosuppression and result in severe damage to the host lung. The current review will examine the most recent epidemiologic studies about the incidence of Pneumocystis in the HIV-positive and HIV-negative populations in the developing and developed world and will detail methods of diagnosis for Pneumocystis pneumonia. Finally, this review aims to summarize the known mediators of immunity to Pneumocystis and detail the pathologic immune response leading to Pneumocystis-related immune reconstitution inflammatory syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.